News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Immunotherapy for brain cancer gets European PRIME status Latest addition to EMA's fast-track for cutting edge drugs
Articles Europe launches new PRIME fast-track for promising medicines Andrew McConaghie reports on a newly-launched plan to speed up access to groundbreaking new medicines in Europe.
News RIF job losses are underway at HHS agencies; reports Reduction in force (RIF) job losses have started in earnest at US federal agencies, including the FDA and CDC, according to media reports.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
